Malignant hyperthermia

Common Name(s)

Malignant hyperthermia

Malignant hyperthermia is a severe reaction to particular drugs used during surgery and other invasive procedures. People at increased risk for this disorder are said to have malignant hyperthermia susceptibility. If given these drugs, these people may experience muscle rigidity, breakdown of muscle fibers, a high fever, increased acid levels in the blood and other tissues, and a rapid heart rate. Without prompt treatment, the complications of malignant hyperthermia can be life-threatening. There are at least six forms of malignant hyperthermia susceptibility, which are associated with mutations in different genes (e.g.,  CACNA1S, RYR1). The susceptibility is inherited in an autosomal dominant fashion. People with certain inherited muscle diseases (e.g., central core disease and multiminicore disease) also have malignant hyperthermia susceptibility.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Malignant hyperthermia" for support, advocacy or research.

Malignant Hyperthermia Association of the United States

The mission of MHAUS is to promote optimum care and scientific understanding of MH and related disorders.

Last Updated: 6 May 2014

View Details
The RYR-1 Foundation

The primary goal of the Foundation is to find a cure for RYR-1 related muscle diseases. To achieve this goal, the Foundation has several missions: 1) Support Research 2) Physician Education 3) Patient/family support and advocacy

Last Updated: 16 Mar 2015

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Malignant hyperthermia" for support, advocacy or research.

Malignant Hyperthermia Association of the United States

The mission of MHAUS is to promote optimum care and scientific understanding of MH and related disorders.

http://www.mhaus.org

Last Updated: 6 May 2014

View Details
The RYR-1 Foundation

The primary goal of the Foundation is to find a cure for RYR-1 related muscle diseases. To achieve this goal, the Foundation has several missions: 1) Support Research 2) Physician Education 3) Patient/family support and advocacy

http://www.ryr1.org

Last Updated: 16 Mar 2015

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

General Resources

North American Malignant Hyperthermia Registry

The Registry's goal is to acquire, analyze, and disseminate case-specific clinical and laboratory information related to malignant hyperthermia susceptibility.

Updated 21 Dec 2012

Go To URL
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Malignant hyperthermia" returned 188 free, full-text research articles on human participants. First 3 results:

Rare postoperative delayed malignant hyperthermia after off-pump coronary bypass surgery and brief review of literature.
 

Author(s): Monish S Raut, Sibashankar Kar, Arun Maheshwari, Ganesh Shivnani, Arun Kumar, Elvin Daniel, Sandeep Joshi, Amit Motihar, Priyanka Gupta

Journal: Ann Card Anaesth. ;19(2):357-62.

 

Postoperative malignant hyperthermia (MH) is a very rare phenomena. It is generally observed within less than an hour after discontinuation of the anesthetic trigger. Present case describes rare delayed postoperative presentation of MH after off-pump coronary bypass surgery. Prompt ...

Last Updated: 7 Apr 2016

Go To URL
Exertional Heat Stroke and Susceptibility to Malignant Hyperthermia in an Athlete: Evidence for a Link?
 

Author(s): Mathias Poussel, Philippe Guerci, Pierre Kaminsky, Marie Heymonet, Nathalie Roux-Buisson, Julien Faure, Emilien Fronzaroli, Bruno Chenuel

Journal: J Athl Train. 2015 Nov;50(11):1212-4.

 

To describe the possible association (pathophysiologic and clinical features) between exertional heat stroke (EHS) and malignant hyperthermia (MH).

Last Updated: 5 Dec 2015

Go To URL
Simple intrapleural hyperthermia at thoracoscopic exploration to treat malignant pleural effusion.
 

Author(s): Youngkyu Moon, Kyung Soo Kim, Jae Kil Park

Journal:

 

Malignant pleural effusion (MPE) occurs at a terminal stage of cancer, and related symptoms may considerably reduce a patient's respiratory function and quality of life. We assessed the benefit of simple intrapleural hyperthermia (SIH) during thoracoscopic exploration for MPE.

Last Updated: 29 Oct 2015

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Malignant hyperthermia" returned 19 free, full-text review articles on human participants. First 3 results:

Malignant hyperthermia: a review.
 

Author(s): Henry Rosenberg, Neil Pollock, Anja Schiemann, Terasa Bulger, Kathryn Stowell

Journal:

 

Malignant hyperthermia (MH) is a pharmacogenetic disorder of skeletal muscle that presents as a hypermetabolic response to potent volatile anesthetic gases such as halothane, sevoflurane, desflurane, isoflurane and the depolarizing muscle relaxant succinylcholine, and rarely, in humans, ...

Last Updated: 5 Aug 2015

Go To URL
[Malignant hyperthermia - problem in dental surgery. An introductory report].
 

Author(s): Ewa KamiƄska, Anna Janas, Piotr Osica

Journal: Dev Period Med. ;18(4):483-8.

 

Malignant hyperthermia is a genetic defect of uncontrolled hypermetabolic skeletal muscle response to anesthetic triggering drugs. Some congenital myopathies are regarded as risk increasing factors. The use of volatile anaesthetics or suxamethonium (succinylcholine) in patients who ...

Last Updated: 16 Apr 2015

Go To URL
Exercise-induced rhabdomyolysis and stress-induced malignant hyperthermia events, association with malignant hyperthermia susceptibility, and RYR1 gene sequence variations.
 

Author(s): Antonella Carsana

Journal: ScientificWorldJournal. 2013 ;2013():531465.

 

Exertional rhabdomyolysis (ER) and stress-induced malignant hyperthermia (MH) events are syndromes that primarily afflict military recruits in basic training and athletes. Events similar to those occurring in ER and in stress-induced MH events are triggered after exposure to anesthetic ...

Last Updated: 11 Mar 2013

Go To URL
 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Malignant Hyperthermia Registry and Genetic Testing
 

Status: Recruiting

Condition Summary: Malignant Hyperthermia

 

Last Updated: 29 Aug 2017

Go to URL
A Case Control Study of Patients With Diagnosis of Malignant Hyperthermia
 

Status: Recruiting

Condition Summary: Malignant Hyperthermia

 

Last Updated: 28 Jul 2017

Go to URL
Congenital Muscle Disease Study of Patient and Family Reported Medical Information
 

Status: Recruiting

Condition Summary: Congenital Muscular Dystrophy (Including Unspecified/Undiagnosed); Dystroglycanopathy; Congenital Fiber Type Disproportion; Rigid Spine Muscular Dystrophy; Congenital Myopathy (Including Unspecified/Undiagnosed); Collagen VI CMD (Ullrich CMD, Intermediate, Bethlem Myopathy); Laminin Alpha 2 Related Congenital Muscular Dystrophy; LAMA2-CMD/Merosin Deficient/MDC1A; Walker-Warburg Syndrome; Muscle-Eye-Brain Disease; Fukuyama/Fukutin Related Muscular Dystrophy; Integrin Alpha 7 Deficiency; Integrin Alpha 9 Deficiency; LMNA-CMD/Lamin A/C/Laminopathy; SEPN1-Related Myopathy; Bethlem Myopathy; Actin Aggregation Myopathy; Cap Disease; Central Core Disease; Centronuclear Myopathy; Core Rod Myopathy; Hyaline Body Myopathy; Multiminicore Myopathy; Myotubular Myopathy; Nemaline Myopathy; Tubular Aggregate Myopathy; Zebra Body Myopathy; Reducing Body Myopathy; Spheroid Body Myopathy; LGMD1B (LMNA); LGMD1E (DES); LGMD2G (TCAP); LGMD2H (TRIM32); LGMD2I (FKRP); LGMD2J (TTN); LGMD2K (POMT1); LGMD2M (FKTN); LGMD2N (POMT2); LGMD2O (POMGnT1); LGMD2P (DAG1); LGMD2Q (PLEC1); LGMD2R (DES); LGMD2S (TRAPPC11); LGMD2T (GMPPB); LGMD2U (ISPD); LGMD2V (GAA); Ullrich Congenital Muscular Dystrophy; Titinopathy; Choline Kinase B Receptor; Emery-Dreifuss Muscular Dystrophy; RYR1 Related Myopathy; SYNE1/Nesprin Related Muscular Dystrophy; Telethonin Related Muscular Dystrophy (TCAP/Titin-Cap); Congenital Myasthenic Syndrome; Escobar Syndrome; Myofibrillar Myopathy; Malignant Hyperthermia; Alpha-Dystroglycan Related Muscular Dystrophy (DAG1, DPM1, DPM2, DPM3, FKRP, FKTN); Alpha-Dystroglycan Related Muscular Dystrophy (GAA, ISPD, LARGE, POMT1, POMT2, POMGnT1); Alpha-Dystroglycan Related Muscular Dystrophy (Unspecified/Undiagnosed/Other)

 

Last Updated: 5 May 2017

Go to URL